Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups

Table 2 Overview of study demographics

Study	Patients included	Mean age [years]	Mean follow-up [years]	% statin use	% PPI use	% diabetes	% male
British Doctors’ Study	5139	61	6	Unknown	Unknown	2	100
US Physicians’ Health Study	22,071	53	5	Unknown	Unknown	2	100
Thrombosis Prevention Trial	5085	57	6.8	Unknown	Unknown	2	100
Hypertension Optimal Treatment Trial	18,790	61	3.8	Unknown	Unknown	8	53
Primary Prevention Project	4495	64	3.6	Unknown	Unknown	17	43
Women’s Health Study	39,876	54	10.1	Unknown	Unknown	3	0
POPADAD trial	1276	60	6.7	Unknown	Unknown	100	44
JPAD trial	2539	65	10.3	26	8.6**	100	55
AAA trial	3350	62	8.2	Unknown	Unknown	3	28
JPPP trial	14,464	71	5	Unknown	Unknown	34	42
ARRIVE trial	12,546	64	5	Unknown	Unknown	0	70
ASCEND trial	15,480	63	7.4	75	Approx. 25	94.1	63
ASPREE trial	19,114	74*	4.7	34	24.7	11	44
all studies included	164,225	62	6.4 (IQR 4.85–7.8)

ISSN: 1741-7015